Developer docs
API playgroundTry for free, no card

Search company profiles

Spectranetics

Full company profile

uuid00063qd

Namestring
Spectranetics
Legal namestring
The Spectranetics Corporation
Company typeenum
Private
Founded yearint
1984
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersColorado Springs, United States
HQ citystring
Colorado Springs
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
laser atherectomy catheters, cardiac lead extraction devices, peripheral vascular intervention, coronary intervention catheters, image-guided therapy devices
Industry3 codes
PRIMARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
SECONDARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiovascular Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Sale of cardiovascular intervention devices including lead extraction tools, laser atherectomy catheters, balloon catheters, and support devices to hospitals and healthcare facilities through Philips Healthcare distribution network.

spectranetics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Spectranetics designs, manufactures, and sells laser-based medical devices and disposable catheters used in three cardiovascular therapy areas: lead management and extraction (laser sheaths, locking devices, extraction catheters, occlusion balloons), peripheral vascular intervention (scoring balloons, drug-coated balloons, laser atherectomy catheters, thrombectomy systems), and coronary intervention (excimer laser systems and laser atherectomy catheters). Its products are sold to hospitals, electrophysiology labs, and cardiac catheterization laboratories, primarily through the Philips Healthcare distribution network following the 2017 acquisition.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Spectranetics, now part of Philips Healthcare, offers a comprehensive portfolio of medical devices focused on image-guided therapy. The portfolio spans three main solution areas: lead management and extraction devices (including laser sheaths, locking devices, and extraction catheters), peripheral intervention products (scoring balloons, drug-coated balloons, atherectomy catheters, and thrombectomy systems), and coronary intervention solutions. The core technology platforms include excimer laser systems (CVX300, LAS-100) used across multiple applications, and the product lineup integrates with Philips imaging systems for precision-guided procedures.

Product and service18 records
1CVX300 Cardiovascular Laser System
CategoryCardiovascular Medical Devices
Description

Excimer laser console for cardiovascular interventions including lead extraction and atherectomy procedures, used by hospitals and cath labs as a capital platform driving laser atherectomy catheters and laser sheaths.

2Philips Laser System Model LAS-100
CategoryCardiovascular Medical Devices
Description

Laser system platform supporting various cardiovascular laser procedures, used in conjunction with Spectranetics atherectomy catheters and laser sheaths.

3ELCA Coronary Laser Atherectomy Catheter
CategoryCardiovascular Medical Devices
Description

Coronary laser atherectomy catheter for ablating calcified lesions and facilitating stent delivery in coronary arteries, available in multiple configurations including 0.9mm and X-80 variants.

4Turbo Family Laser Atherectomy and Guide Catheters (Turbo-Elite, Turbo-Power, Turbo-Booster, Turbo-Tandem)
CategoryPeripheral Vascular Devices
Description

Family of laser atherectomy and guide catheters (Turbo-Elite, Turbo-Power, Turbo-Booster, Turbo-Tandem) for treating peripheral artery lesions, with combined atherectomy and guide catheter variants to streamline peripheral interventions.

5Glidelight Laser Sheath
CategoryLead Management Devices
Description

Laser sheath system for lead extraction procedures that combines mechanical and laser energy to free cardiac leads from vascular adhesions, used in electrophysiology labs treating CIED infections and abandoned leads.

6SLS II Laser Sheath
CategoryLead Management Devices
Description

Second-generation laser sheath for lead extraction that combines mechanical telescoping sheaths with excimer laser energy for safer, more efficient lead removal.

7Bridge Occlusion Balloon (Bridge / Bridge Plus)
CategoryLead Management Devices
Description

Occlusion balloon (with Bridge Prep Kit) used to manage rare but life-threatening superior vena cava (SVC) tears during lead extraction procedures, now upgraded to Bridge Plus.

8LLD Lead Locking Device
CategoryLead Management Devices
Description

Device that provides an internal locking mechanism for cardiac lead extraction procedures, stabilizing the lead for safe removal.

9TightRail Rotating Dilator Sheath Family (TightRail, TightRail Mini, TightRail Sub-C)
CategoryLead Management Devices
Description

Mechanically rotating dilator sheath family (standard, Mini, and Sub-C variants) for facilitating lead extraction through calcified tissue.

10Quick-Cross Support Catheter Family (Quick-Cross, Quick-Cross Extreme, Quick-Cross Select)
CategoryPeripheral Vascular Devices
Description

Support catheters including Extreme (high-support for challenging lesion crossing) and Select (steerable, variable tip shaping) variants, plus the Quick-Cross Capture guidewire retriever, used for guidewire support and navigation during peripheral vascular interventions.

11QuickCat Extraction Catheter
CategoryLead Management Devices
Description

Extraction catheter designed for lead removal procedures in cardiac lead extraction workflows.

12SightRail Dilator Sheath Set
CategoryLead Management Devices
Description

Dilator sheath system used during lead extraction procedures to support lead removal.

13TorqMax Lead Management Device
CategoryLead Management Devices
Description

Lead management device used during cardiac lead extraction procedures to facilitate lead removal.

14Quick-Access Needle Holder
CategoryLead Management Devices
Description

Surgical instrument used during lead extraction procedures.

15VisiSheath Dilator Sheath
CategoryLead Management Devices
Description

Dilator sheath with visualization capabilities for lead extraction procedures, supporting direct visualization during lead removal.

16AngioSculpt Scoring Balloon Catheter Family (PTA, PTCA, AngioSculptX Drug-Coated)
CategoryPeripheral and Coronary Vascular Devices
Description

Scoring balloon catheter family for PTA (peripheral) and PTCA (coronary) interventions, available in RX and OTW configurations, with the AngioSculptX drug-coated variant combining mechanical scoring with drug delivery.

17Stellarex Drug-Coated Angioplasty Balloon
CategoryPeripheral Vascular Devices
Description

Drug-coated angioplasty balloon available in 0.014 and 0.035 inch profiles (0.035 OTW) for peripheral artery disease treatment.

18ThromCat XT Thrombus Removal System
CategoryPeripheral Vascular Devices
Description

Mechanical thrombectomy system for removing thrombus from peripheral vessels.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthersAnnounced on2017-08-09
Description

Philips acquired Spectranetics Corporation in August 2017 for approximately $2.2 billion, integrating Spectranetics into Philips' Image Guided Therapy business unit. Spectranetics became part of Royal Philips Healthcare, operating under the Philips brand with its products distributed through Philips healthcare channels.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Penumbra's Indigo thrombectomy system is a direct competitor to Spectranetics' ThromCat XT for peripheral thrombus removal, and the company is expanding from neurovascular into peripheral vascular intervention, overlapping with the same hospital buying centers.

2Asahi Intecc Co., Ltd.
TypeEmerging player
Description

Asahi Intecc is a leading guidewire and microcatheter manufacturer that competes with Spectranetics' Quick-Cross support catheter family, particularly in the peripheral vascular intervention segment where its wires are commonly used alongside or instead of Spectranetics' catheter portfolio.

TypeDirect peer
Description

Shockwave's intravascular lithotripsy (IVL) catheters compete with Spectranetics' laser atherectomy for calcium modification in both coronary and peripheral vessels, representing one of the fastest-growing alternative modalities for the same complex lesion indication.

TypeDirect peer
Description

AngioDynamics competes with Spectranetics in peripheral vascular intervention (angiographic catheters, thrombolytics, and the recently divested mechanical thrombectomy line) and has overlapping relationships with vascular surgeons and interventional radiologists.

TypeBroad incumbent
Description

Medtronic competes directly with Spectranetics in lead extraction (Evolution mechanical sheaths), coronary intervention (PCI catheters, scoring balloons), and DCB peripheral intervention (IN.PACT), and is the dominant CIED manufacturer whose lead portfolio drives demand for extraction tools.

TypeDirect peer
Description

BD's Lutonix drug-coated balloon competes head-to-head with Spectranetics' Stellarex DCB in the peripheral artery disease market, and BD also offers Rotarex mechanical thrombectomy devices that overlap with Spectranetics' ThromCat XT.

7Abbott Laboratories
TypeBroad incumbent
Description

Abbott is a large incumbent in interventional cardiology with overlapping products in coronary intervention (tretto/tri-rail/NC balloons, PressureWire FFR) and peripheral vascular intervention, and competes for cath-lab equipment capital budgets that Spectranetics' CVX300 system also targets.

TypeDirect peer
Description

CSI's Diamondback 360 orbital atherectomy system is a direct competitor to Spectranetics' Turbo-Elite and Turbo-Power laser atherectomy catheters in the peripheral artery disease treatment market, addressing the same vessel preparation use case in cath labs and office-based labs.

TypeBroad incumbent
Description

Boston Scientific is a broad cardiovascular incumbent that overlaps with Spectranetics in peripheral intervention (Ranger DCB, atherectomy portfolio), coronary intervention (PCI catheters), and structural heart — competing for the same cath-lab and EP-lab budgets and increasingly bundling imaging-guided solutions.

TypeEmerging player
Description

While primarily known for structural heart (TAVR/surgical valves), Edwards increasingly overlaps with Spectranetics in the interventional cardiology/structural heart space and competes for the same cath-lab and hybrid OR capital where lead extraction and complex PCI procedures are performed.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature12 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spectranetics

Cardiovascular Medical Devicesspectranetics.com

Spectranetics firmographics

Firmographics
Name
Spectranetics
Legal name
The Spectranetics Corporation
Website
https://spectranetics.com
Company type
Private
Founded year
1984
Operating status
Acquired
Headcount range
251–500 employees
Ownership category
akta.pro rank

Spectranetics industry classification

Industry
Product category
Cardiovascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
SECONDARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Laser atherectomy catheters
  • Cardiac lead extraction devices
  • Peripheral vascular intervention
  • Coronary intervention catheters
  • Image-guided therapy devices

Where Spectranetics is headquartered

Location

Headquarters

HQ city
Colorado Springs
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Spectranetics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Sale of cardiovascular intervention devices including lead extraction tools, laser atherectomy catheters, balloon catheters, and support devices to hospitals and healthcare facilities through Philips Healthcare distribution network.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Spectranetics product offering

Product offering

Core offering

Spectranetics designs, manufactures, and sells laser-based medical devices and disposable catheters used in three cardiovascular therapy areas: lead management and extraction (laser sheaths, locking devices, extraction catheters, occlusion balloons), peripheral vascular intervention (scoring balloons, drug-coated balloons, laser atherectomy catheters, thrombectomy systems), and coronary intervention (excimer laser systems and laser atherectomy catheters). Its products are sold to hospitals, electrophysiology labs, and cardiac catheterization laboratories, primarily through the Philips Healthcare distribution network following the 2017 acquisition.

Product overview

Spectranetics, now part of Philips Healthcare, offers a comprehensive portfolio of medical devices focused on image-guided therapy. The portfolio spans three main solution areas: lead management and extraction devices (including laser sheaths, locking devices, and extraction catheters), peripheral intervention products (scoring balloons, drug-coated balloons, atherectomy catheters, and thrombectomy systems), and coronary intervention solutions. The core technology platforms include excimer laser systems (CVX300, LAS-100) used across multiple applications, and the product lineup integrates with Philips imaging systems for precision-guided procedures.

Differentiator

Problem solved

Functional benefit

Products and services

  • CVX300 Cardiovascular Laser System Excimer laser console for cardiovascular interventions including lead extraction and atherectomy procedures, used by hospitals and cath labs as a capital platform driving laser atherectomy catheters and laser sheaths.
  • Philips Laser System Model LAS-100 Laser system platform supporting various cardiovascular laser procedures, used in conjunction with Spectranetics atherectomy catheters and laser sheaths.
  • ELCA Coronary Laser Atherectomy Catheter Coronary laser atherectomy catheter for ablating calcified lesions and facilitating stent delivery in coronary arteries, available in multiple configurations including 0.9mm and X-80 variants.
  • Turbo Family Laser Atherectomy and Guide Catheters (Turbo-Elite, Turbo-Power, Turbo-Booster, Turbo-Tandem) Family of laser atherectomy and guide catheters (Turbo-Elite, Turbo-Power, Turbo-Booster, Turbo-Tandem) for treating peripheral artery lesions, with combined atherectomy and guide catheter variants to streamline peripheral interventions.
  • Glidelight Laser Sheath Laser sheath system for lead extraction procedures that combines mechanical and laser energy to free cardiac leads from vascular adhesions, used in electrophysiology labs treating CIED infections and abandoned leads.
  • SLS II Laser Sheath Second-generation laser sheath for lead extraction that combines mechanical telescoping sheaths with excimer laser energy for safer, more efficient lead removal.
  • Bridge Occlusion Balloon (Bridge / Bridge Plus) Occlusion balloon (with Bridge Prep Kit) used to manage rare but life-threatening superior vena cava (SVC) tears during lead extraction procedures, now upgraded to Bridge Plus.
  • LLD Lead Locking Device Device that provides an internal locking mechanism for cardiac lead extraction procedures, stabilizing the lead for safe removal.
  • TightRail Rotating Dilator Sheath Family (TightRail, TightRail Mini, TightRail Sub-C) Mechanically rotating dilator sheath family (standard, Mini, and Sub-C variants) for facilitating lead extraction through calcified tissue.
  • Quick-Cross Support Catheter Family (Quick-Cross, Quick-Cross Extreme, Quick-Cross Select) Support catheters including Extreme (high-support for challenging lesion crossing) and Select (steerable, variable tip shaping) variants, plus the Quick-Cross Capture guidewire retriever, used for guidewire support and navigation during peripheral vascular interventions.
  • QuickCat Extraction Catheter Extraction catheter designed for lead removal procedures in cardiac lead extraction workflows.
  • SightRail Dilator Sheath Set Dilator sheath system used during lead extraction procedures to support lead removal.
  • TorqMax Lead Management Device Lead management device used during cardiac lead extraction procedures to facilitate lead removal.
  • Quick-Access Needle Holder Surgical instrument used during lead extraction procedures.
  • VisiSheath Dilator Sheath Dilator sheath with visualization capabilities for lead extraction procedures, supporting direct visualization during lead removal.
  • AngioSculpt Scoring Balloon Catheter Family (PTA, PTCA, AngioSculptX Drug-Coated) Scoring balloon catheter family for PTA (peripheral) and PTCA (coronary) interventions, available in RX and OTW configurations, with the AngioSculptX drug-coated variant combining mechanical scoring with drug delivery.
  • Stellarex Drug-Coated Angioplasty Balloon Drug-coated angioplasty balloon available in 0.014 and 0.035 inch profiles (0.035 OTW) for peripheral artery disease treatment.
  • ThromCat XT Thrombus Removal System Mechanical thrombectomy system for removing thrombus from peripheral vessels.

Companies that use Spectranetics

Customer profile

Segments3 records

Ideal customer profiles3 records

Spectranetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature12 records

Spectranetics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Philips HealthcarecoreOthers · 9 August 2017Philips acquired Spectranetics Corporation in August 2017 for approximately $2.2 billion, integrating Spectranetics into Philips' Image Guided Therapy business unit. Spectranetics became part of Royal Philips Healthcare, operating under the Philips brand with its products distributed through Philips healthcare channels.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Spectranetics competitors and assessment

Company assessment

Emerging players

  • Penumbra, Inc. Penumbra's Indigo thrombectomy system is a direct competitor to Spectranetics' ThromCat XT for peripheral thrombus removal, and the company is expanding from neurovascular into peripheral vascular intervention, overlapping with the same hospital buying centers.
  • Asahi Intecc Co., Ltd. Asahi Intecc is a leading guidewire and microcatheter manufacturer that competes with Spectranetics' Quick-Cross support catheter family, particularly in the peripheral vascular intervention segment where its wires are commonly used alongside or instead of Spectranetics' catheter portfolio.
  • Edwards Lifesciences Corporation: While primarily known for structural heart (TAVR/surgical valves), Edwards increasingly overlaps with Spectranetics in the interventional cardiology/structural heart space and competes for the same cath-lab and hybrid OR capital where lead extraction and complex PCI procedures are performed.

Direct peers

  • Shockwave Medical (Johnson & Johnson): Shockwave's intravascular lithotripsy (IVL) catheters compete with Spectranetics' laser atherectomy for calcium modification in both coronary and peripheral vessels, representing one of the fastest-growing alternative modalities for the same complex lesion indication.
  • AngioDynamics, Inc. AngioDynamics competes with Spectranetics in peripheral vascular intervention (angiographic catheters, thrombolytics, and the recently divested mechanical thrombectomy line) and has overlapping relationships with vascular surgeons and interventional radiologists.
  • Becton, Dickinson and Company (BD): BD's Lutonix drug-coated balloon competes head-to-head with Spectranetics' Stellarex DCB in the peripheral artery disease market, and BD also offers Rotarex mechanical thrombectomy devices that overlap with Spectranetics' ThromCat XT.
  • Cardiovascular Systems, Inc. (CSI / Abbott): CSI's Diamondback 360 orbital atherectomy system is a direct competitor to Spectranetics' Turbo-Elite and Turbo-Power laser atherectomy catheters in the peripheral artery disease treatment market, addressing the same vessel preparation use case in cath labs and office-based labs.

Broad incumbents

  • Medtronic plc: Medtronic competes directly with Spectranetics in lead extraction (Evolution mechanical sheaths), coronary intervention (PCI catheters, scoring balloons), and DCB peripheral intervention (IN.PACT), and is the dominant CIED manufacturer whose lead portfolio drives demand for extraction tools.
  • Abbott Laboratories: Abbott is a large incumbent in interventional cardiology with overlapping products in coronary intervention (tretto/tri-rail/NC balloons, PressureWire FFR) and peripheral vascular intervention, and competes for cath-lab equipment capital budgets that Spectranetics' CVX300 system also targets.
  • Boston Scientific Corporation: Boston Scientific is a broad cardiovascular incumbent that overlaps with Spectranetics in peripheral intervention (Ranger DCB, atherectomy portfolio), coronary intervention (PCI catheters), and structural heart — competing for the same cath-lab and EP-lab budgets and increasingly bundling imaging-guided solutions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Spectranetics social profiles

Digital presence

Spectranetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spectranetics leadership team

Management profile

Number of profiles

Profiles1 record

Spectranetics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spectranetics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spectranetics

What does Spectranetics do?

Spectranetics designs, manufactures, and sells laser-based medical devices and disposable catheters used in three cardiovascular therapy areas: lead management and extraction (laser sheaths, locking devices, extraction catheters, occlusion balloons), peripheral vascular intervention (scoring balloons, drug-coated balloons, laser atherectomy catheters, thrombectomy systems), and coronary intervention (excimer laser systems and laser atherectomy catheters). Its products are sold to hospitals, electrophysiology labs, and cardiac catheterization laboratories, primarily through the Philips Healthcare distribution network following the 2017 acquisition.

Is Spectranetics a public or private company?

Spectranetics is a private company. It is classified as corporate owned and is currently acquired.

When was Spectranetics founded?

Spectranetics was founded in 1984. It employs 251 to 500 people.

Where is Spectranetics based?

Spectranetics is headquartered in Colorado Springs, United States, in the North America region.

How does Spectranetics make money?

One revenue line is on record: medical Device Sales.

Who are Spectranetics's main competitors?

Emerging players on record are Penumbra, Inc., Asahi Intecc Co., Ltd. and Edwards Lifesciences Corporation. Direct peers are Shockwave Medical (Johnson & Johnson), AngioDynamics, Inc., Becton, Dickinson and Company (BD) and Cardiovascular Systems, Inc. (CSI / Abbott). Broad incumbents are Medtronic plc, Abbott Laboratories and Boston Scientific Corporation.

Does Spectranetics have an API?

No public API is recorded for Spectranetics.

What industry is Spectranetics in?

Spectranetics's product category is Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAKABAB, Interventional Cardiology (PCI/Structural Heart), with a secondary code of HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
JaccNovel Use of a Rotating Mechanical Dilator Sheath for S-ICD Lead ExtractionA medical case report describes the successful extraction of a subcutaneous implantable cardioverter-defibrillator (S-ICD) lead from a 53-year-old patient using a novel rotating mechanical dilator sheath after standard traction failed due to adhesions. The procedure, which involved Boston Scientific S-ICD hardware and Spectranetics extraction tools, resolved inappropriate device shocks without complications. This highlights an emerging technique for managing complex S-ICD extractions as these devices age in the growing patient population.PR NewswirePhilips showcases integrated vascular solutions at VEITH 2017Philips will showcase its integrated vascular solutions at the 2017 VEITHsymposium in New York, including interventional X-ray systems, devices, and software. The company will also launch PVDandMe.com, a patient education website for peripheral vascular disease, and highlight its Spectranetics acquisition.PR NewswirePhilips showcases unique portfolio of cardiovascular care solutions at TCT 2017Royal Philips announced it will showcase its expanded image-guided therapy portfolio at the TCT 2017 annual conference in Denver, Colorado (October 29 – November 2, 2017), highlighting cardiac and endovascular care solutions including its Azurion platform and Dynamic Coronary Roadmap 2.0 with FFR/iFR Roadmap, which recently received FDA 510(k) clearance. The company also featured products from its recent acquisition of Spectranetics, including the Stellarex drug-coated balloon for peripheral vascular disease, positioning itself as a comprehensive provider of integrated cardiovascular solutions. Philips emphasized that its portfolio aims to help clinicians decide, guide, treat, and confirm appropriate procedures while reducing healthcare costs, addressing a market where approximately 2,200 Americans die daily from cardiovascular disease.PR NewswireEfficacy of Philips' Stellarex .035" low-dose drug-coated balloon demonstrated in clinical trial at two yearsRoyal Philips announced two-year results from the ILLUMENATE European randomized clinical trial demonstrating that 75.9% of patients treated with Stellarex drug-coated balloon maintained blood flow through treated arteries at 24 months, compared to 61.0% for uncoated balloon angioplasty. The trial enrolled 328 peripheral arterial disease patients across 18 centers in Germany and Austria, establishing Stellarex as the first low-dose DCB to show significant treatment effect at two years. Philips completed its acquisition of Spectranetics in August 2017, shortly after Spectranetics received FDA approval for Stellarex in the U.S. in July 2017.PR NewswirePhilips showcases integrated vascular solutions at VIVA 2017 to advance image-guided therapy proceduresRoyal Philips showcased its expanded interventional vascular portfolio at the VIVA 2017 Annual Conference in Las Vegas, including products from its recent acquisition of Spectranetics. The company highlighted its Azurion image-guided therapy platform, Phoenix atherectomy system, and Spectranetics' Stellarex drug-coated balloon, which received FDA approval in July 2017. Clinical data from the ILLUMENATE European randomized trial evaluating Stellarex's two-year efficacy in treating peripheral arterial disease was also presented at the conference.WebWirePhilips completes acquisition of The Spectranetics CorporationPhilips completed its acquisition of Spectranetics, a vascular intervention and lead management company, with financials consolidated as of August 9, 2017. The deal, paid $38.50 per share, is expected to be accretive to Philips by 2018. Spectranetics projects 2017 sales of about $300 million.WebWirePhilips successfully completes tender offer for The Spectranetics CorporationPhilips completed its tender offer to buy all outstanding Spectranetics shares for $38.50 per share, with 85.5% of shares tendered. The merger will make Spectranetics a wholly owned Philips subsidiary, and its NASDAQ listing will be cancelled.PhilipsPhilips completes acquisition of The Spectranetics CorporationPhilips completed its acquisition of Spectranetics on August 9, 2017, paying $38.50 per share in cash. Spectranetics' financial results will be consolidated into Philips' Image-Guided Therapy business group, with the deal expected to be accretive to revenue, EBITA margin, and EPS by 2018. The acquisition is expected to drive revenue growth in a EUR 6+ billion market.PR NewswireFinancialinsiders.com Earnings Recap Week Ending June 30th, 2017U.S. stocks dropped sharply on Thursday with the Dow Jones experiencing its biggest one-day decline in more than a month, driven by a technology sector sell-off, while 34 of the largest U.S. banks successfully passed the Federal Reserve's stress tests. The week saw multiple major M&A announcements including Staples agreeing to sell itself to private equity firm Sycamore Partners for $6.9 billion, Koninklijke Philips NV acquiring U.S. cardiovascular device maker Spectranetics Corp for approximately $2.16 billion, and Walgreens Boots Alliance terminating its planned acquisition of Rite Aid Corporation, instead agreeing to purchase 2,186 Rite-Aid stores for $5.18 billion with a $325 million termination fee payable to Rite Aid.InvestorsCould Philips' Rivals Stage A Coup For Spectranetics?Philips is pursuing a bid for heart device-maker Spectranetics, with analysts saying rivals like Boston Scientific, Abbott, and Medtronic are unlikely to block it. Spectranetics stock rose 26.2% to 38.35 on the market.